2025-10-09 - Analysis Report
Okay, here's an analysis of Transmedics Group Inc. (TMDX), incorporating all the data you provided. I'll start with the numbers, add commentary, and provide a final summary.

**Report on Transmedics Group Inc. (TMDX)**

Transmedics Group Inc. is a medical technology company revolutionizing organ transplantation through its Organ Care System (OCS).

**1. Performance vs. S&P 500 (VOO)**

*   **Cumulative Return (TMDX):** 195.71%
*   **Cumulative Return (VOO):** 74.86%
*   **Absolute Divergence:** 116.1% (TMDX significantly outperforms VOO)
*   **Relative Divergence:** 59.2% (TMDX's outperformance is positioned in the upper half of its historical divergence range compared to VOO)

**Alpha and Beta Analysis**

| Year        | CAGR     | MDD   | Alpha   | Beta   | Cap(B) |
| ----------- | -------- | ----- | ------- | ------ | ------ |
| 2019-2021   | -18.0%   | 83.5% | -61.0%  | -0.0   | 0.7    |
| 2020-2022   | 94.0%    | 83.5% | 95.0%   | 0.0    | 2.1    |
| 2021-2023   | 65.0%    | 80.5% | 64.0%   | 0.1    | 2.7    |
| 2022-2024   | 130.0%   | 85.5% | 109.0%  | 0.1    | 2.1    |
| 2023-2025   | 116.0%   | 85.5% | 52.0%   | 0.3    | 4.0    |

*   **Analysis:** TMDX has shown periods of strong growth (high CAGR) but also significant volatility (high MDD).  The Alpha values are generally very positive, indicating TMDX's returns are largely independent of market movements. The Beta values are very low, suggesting low correlation with the overall market, but has recently been increasing. Market Cap has grown over time.

**2. Recent Stock Price Movements**

*   **Current Price:** $118.06
*   **Last Market Data:** {'price': 118.06, 'previousClose': 115.18, 'change': 2.5} -  Significant positive change from previous close indicates a potential short-term catalyst.
*   **5-day Moving Average:** $115.79
*   **20-day Moving Average:** $116.71
*   **60-day Moving Average:** $115.77

*   **Analysis:** The current price is above all three moving averages, suggesting a short-term bullish trend. The recent price jump further reinforces this.

**3. Technical Indicators and Return Expectations**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended) - Indicates a relatively favorable risk environment for investment.
*   **RSI:** 44.61 -  Neutral, not overbought or oversold.
*   **PPO:** 0.12% -  Suggests a slight upward trend in price momentum.
*   **Hybrid Signal:** "cash\_0%_Buy 100% of cash (8 shares - Very Safe - MRI:0.90)" -  Strong buy signal based on the algorithm.
*   **20-day Relative Divergence Change:** 0.2 (+) - Short-term upward momentum relative to the benchmark.
*   **Expected Return:** 51.4% -  Significant potential outperformance vs. S&P 500 over a 2+ year investment horizon.

*   **Analysis:**  The high MRI and Hybrid Signal suggest favorable conditions for investment.  The positive divergence change and strong expected return further support a bullish outlook. The recent price change of 2.5 points reinforces the positive sentiment.

**4. Recent News & Significant Events**

*   **Positive Coverage:** Articles highlighting TMDX as a strong growth stock, potentially undervalued, and one to hold for the long term.
*   **Analyst Target Price Increase:** Argus Research raising the target price to $121.00.
*   **Strategic Partnership:** Collaboration with Mercedes-Benz for organ transport in Italy.

*   **Analysis:** The news flow is overwhelmingly positive, focusing on growth potential, undervaluation, and strategic initiatives.  The analyst upgrade is a key validation. The Mercedes-Benz partnership enhances logistics and market presence.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (Mean Rating: 1.82)
*   **Target Price:** Average $140.67 (Upside potential)
*   **Recent Rating Changes:**  Not specified, implying stable positive sentiment.

*   **Analysis:** Strong analyst consensus supports a positive outlook, with a significant upside potential based on the average target price.

**5. Recent Earnings Analysis**

| 날짜       | EPS  | 예상 EPS |
| ---------- | ---- | -------- |
| 2025-07-30 | 0.92 | 0.48     |
| 2025-05-08 | 0.7  | 0.29     |
| 2025-02-27 | 0.19 | 0.22     |
| 2024-10-28 | 0.12 | 0.29     |
| 2024-07-31 | 0.35 | 0.21     |

*   **Analysis:** TMDX has significantly exceeded EPS expectations in the last two quarters, suggesting strong operational performance. Prior to that, results were mixed.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue  | Profit Margin |
| ---------- | -------- | ------------- |
| 2025-06-30 | $0.16B   | 61.38%        |
| 2025-03-31 | $0.14B   | 61.47%        |
| 2024-12-31 | $0.12B   | 59.21%        |
| 2024-09-30 | $0.11B   | 55.94%        |
| 2024-06-30 | $0.11B   | 60.59%        |

**Capital and Profitability:**

| Quarter    | Equity   | ROE     |
| ---------- | -------- | ------- |
| 2025-06-30 | $0.32B   | 10.97%  |
| 2025-03-31 | $0.27B   | 9.64%   |
| 2024-12-31 | $0.23B   | 3.00%   |
| 2024-09-30 | $0.21B   | 2.01%   |
| 2024-06-30 | $0.19B   | 6.42%   |

*   **Analysis:**  Revenue is consistently growing. Profit margins are very high and relatively stable. Equity is increasing, and ROE has recently jumped up, indicating improved efficiency in generating profit from equity.

**7. Overall Summary**

Transmedics Group Inc. (TMDX) presents a compelling investment case based on the provided data.

*   **Strong Outperformance:** TMDX has significantly outperformed the S&P 500 (VOO) with a large cumulative return.
*   **Positive Momentum:** Recent price action, moving averages, and technical indicators suggest a short-term bullish trend.
*   **Favorable Sentiment:** Analyst ratings, news coverage, and a high MRI score indicate positive market sentiment and a supportive investment environment.
*   **Solid Financials:** Revenue growth, high profit margins, increasing equity, and improving ROE demonstrate strong financial health.
*   **Earnings Surprise:** Recent EPS beats suggest the company is exceeding expectations.
*   **Strategic Initiatives:** The Mercedes-Benz partnership enhances logistical capabilities and market reach.

**Recommendation:**  Based on the comprehensive analysis, TMDX appears to be a promising investment opportunity. The strong growth potential, positive market sentiment, and solid financial performance warrant a positive outlook. It is important to note the high MDD and that past performance does not guarantee future results. Also, note the Beta is increasing which means more correlation with the general market.

